COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off our Print & eBook bundle option. Terms & conditions.
Equitable Access to High-Cost Pharmaceuticals - 1st Edition - ISBN: 9780128119457, 9780128119624

Equitable Access to High-Cost Pharmaceuticals

1st Edition

0.0 star rating Write a review
Editor: Zaheer-Ud-Din Babar
Paperback ISBN: 9780128119457
eBook ISBN: 9780128119624
Imprint: Academic Press
Published Date: 21st February 2018
Page Count: 238
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

Key Features

  • Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
  • Incorporates existing guidelines and recommendations by international organizations
  • Compares and contrasts how different countries fund and police high-cost drug access
  • Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
  • Reviews novel pharmaceuticals of current research interest


Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics

Table of Contents

1. Access to High Cost Medicines: An Overview
2. Health Technology Assessment
3. High-Cost Medicines in England
4. Managed Entry Agreements and High Cost Medicines (European Perspective)
5. Setting a Public Health Agenda to Support Access to High-Cost Medicines
6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines
7. Access to High Price Medicines in Portugal
8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
9. Equitable Access to Biosimilars: An Overview
10. Access to High-Cost Medicines in Europe
11. Access to High-Cost Medicines in Australia
12. Access to High-Cost Medicines in New Zealand
13. Access to High-Cost Medicines in Wales


No. of pages:
© Academic Press 2018
21st February 2018
Academic Press
Paperback ISBN:
eBook ISBN:

About the Editor

Zaheer-Ud-Din Babar

Zaheer-Ud-Din Babar is Professor in Medicines and Healthcare at the Department of Pharmacy, University of Huddersfield, United Kingdom. He is globally recognized for his research in pharmaceutical policy and practice, including the quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. Previously he was the Head of Pharmacy Practice at School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a Ph.D. in pharmacy practice, Dr. Babar is the recipient of prestigious “Research Excellence Award” from the University of Auckland. He has active research collaborations and linkages in over 30 countries including in World’s leading Universities such as Boston University School of Public Health, Harvard Medical School, Austrian Health Institute, University of Auckland, Monash University and at the University of Sydney. He has published over 150 papers, book chapters, conference papers including in high impact journals such as PLoS Medicine and in Lancet Oncology. Dr. Babar has acted as an advisor for World Health Organization, Health Action International, the International Union Against Tuberculosis and Lung Disease, World Bank, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. His recent work includes a number of high-quality books including "Economic evaluation of pharmacy services", ”Pharmaceutical prices in 21st century”, “ Pharmacy Practice Research Methods” and “Pharmaceutical policies in countries with developing healthcare systems. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe. He is the Editor in Chief of Encyclopedia of Pharmacy Practice and Clinical Pharmacy, which is due to be published by Elsevier in early 2019.The Encyclopedia is comprehensive in nature and it aims to cover multiple stream and domains including pharmacy practice, sociobehavioural, and administrative pharmacy, pharmacoepidemiology, clinical pharmacy and therapeutics and issues related to pharmacy education, professional standards, and workforce. Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at

Affiliations and Expertise

Department of Pharmacy, University of Huddersfield, Huddersfield, UK and Founding editor, Journal of Pharmaceutical Policy and Practice


"Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges." --Aris Angelis, The London School of Economics and Political Science

Ratings and Reviews